Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

Organovo (ONVO) Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under this transaction, Organovo will receive an ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

Following the announcement, shares in Organovo were trading a hefty 270% higher by lunchtime Tuesday. The deal will see Lilly acquire Organovo’s FXR program, including its lead asset, FXR314. All the ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will provide an ...

Objective Dysregulated cellular metabolism is a distinct hallmark of human colorectal cancer (CRC). However, metabolic programme rewiring during tumour progression has yet to be fully understood.

A diverse array of microbial organisms colonizes the human body, collectively known as symbiotic microbial communities. Among the various pathogen infections that hosts encounter, viral infections ...

App Store and the Apple logo are trademarks of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC. © carsales.com.au Pty Ltd 1999-2025 In ...

In the spirit of reconciliation we acknowledge the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and ...